.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
QuintilesIMS
Daiichi Sankyo
Fish and Richardson
Boehringer Ingelheim
Covington
Johnson and Johnson
Federal Trade Commission
Colorcon
US Army

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204491

« Back to Dashboard

NDA 204491 describes RALOXIFENE HYDROCHLORIDE, which is a drug marketed by Amneal Pharms, Aurobindo Pharma Ltd, Glenmark Pharms Ltd, Invagen Pharms, Sciegen Pharms Inc, Teva Pharms Usa, and Watson Labs Inc, and is included in seven NDAs. It is available from eighteen suppliers. Additional details are available on the RALOXIFENE HYDROCHLORIDE profile page.

The generic ingredient in RALOXIFENE HYDROCHLORIDE is raloxifene hydrochloride. There are sixteen drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the raloxifene hydrochloride profile page.

Summary for 204491

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Therapeutic Class:Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers)
Formulation / Manufacturing:see details

Pharmacology for NDA: 204491

Suppliers and Packaging for NDA: 204491

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RALOXIFENE HYDROCHLORIDE raloxifene hydrochloride TABLET;ORAL 204491 ANDA Glenmark Pharmaceuticals Inc., USA 68462-393 68462-393-90 90 TABLET, FILM COATED in 1 BOTTLE (68462-393-90)
RALOXIFENE HYDROCHLORIDE raloxifene hydrochloride TABLET;ORAL 204491 ANDA Glenmark Pharmaceuticals Inc., USA 68462-393 68462-393-10 1000 TABLET, FILM COATED in 1 BOTTLE (68462-393-10)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength60MG
Approval Date:Mar 22, 2016TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Harvard Business School
Accenture
Covington
Johnson and Johnson
US Army
Citi
Merck
Novartis
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot